Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

By sjmartinez • March 3, 2023

Hecht JR, Raman SS, Chan A, Kalinsky K, Baurain JF, Jimenez MM, Garcia MM, Berger MD, Lauer UM, Khattak A, Carrato A, Zhang Y, Liu K, Cha E, Keegan A, Bhatta S, Strassburg CP, Roohullah A. Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. ESMO Open. 2023 Feb 28;8(2):100884. doi: 10.1016/j.esmoop.2023.100884. Epub ahead of print. PMID: 36863095.

Tags: breast neoplasms, drug therapy combination, Gastrointestinal neoplasms, Hematology/Oncology, Publications, viral immunotherapy, virotherapy

Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors

Sarkar S, Sedrak MS, Carroll JE, Schechter C, Muss HB, Mandelblatt JS. Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors. JAMA Netw[...]

Engineered stem cell-derived CD16-enhanced universal NKT cells improve monoclonal antibody-based cancer immunotherapy

Li YR, Zhu Y, Yu Y, Kramer A, Shao Z, Chen Y, Shen X, Zhang C, Ma N, Zhao A, Ochoa CJ, DiBernardo GA, Yuen[...]

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

Paulson S, Ikeda M, Shen L, Stein A, Macarulla T, Milella M, Golan T, Wainberg Z, Taieb J, Wang L, Polydoros F, Abecunas C, López[...]